Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
- 1 August 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 22 (8), 1486-1496
- https://doi.org/10.1681/asn.2010111158
Abstract
The tyrosine kinase inhibitor imatinib is beneficial in experimental renal diseases, but the effect of the new tyrosine kinase inhibitor nilotinib on the progression of renal failure is unknown. We administered either nilotinib or vehicle to Sprague–Dawley rats beginning 2 weeks after 5/6 nephrectomy (Nx) or laparotomy and continuing for 8 weeks. Serum creatinine levels were significantly lower in the nilotinib group after 6 and 8 weeks of treatment. Furthermore, nilotinib-treated rats had less proteinuria, attenuated glomerulosclerosis and tubulointerstitial damage, and reduced macrophage infiltration into the tubulointerstitium. Treatment with nilotinib also significantly decreased renal cortical expression of profibrogenic genes, such as IL-1β and monocyte chemotactic protein-1, which correlated closely with the tubulointerstitial damage score and ED1-positive macrophages score. In addition, nilotinib treatment significantly prolonged survival. Taken together, these results suggest that nilotinib may limit the progression of chronic kidney disease.Keywords
This publication has 50 references indexed in Scilit:
- Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesisAmerican Journal of Physiology-Renal Physiology, 2010
- IL-1RI deficiency ameliorates early experimental renal interstitial fibrosisNephrology Dialysis Transplantation, 2009
- Imatinib Suppresses Cryoglobulinemia and Secondary Membranoproliferative GlomerulonephritisJournal of the American Society of Nephrology, 2009
- Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritisJCI Insight, 2006
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 RatsHypertension, 2006
- Amelioration of autoimmune nephritis by imatinib in MRL/lpr miceArthritis & Rheumatism, 2005
- Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In VivoHypertension, 2004
- Pharmacology of imatinib (STI571)European Journal of Cancer, 2002
- Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblastsKidney International, 1995